BiotechTube

Elotuzumab + Lenalidomide + Dexamethasone

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smoldering Myeloma

Conditions

Smoldering Myeloma, Smoldering Multiple Myeloma

Trial Timeline

Dec 11, 2014 → Jan 26, 2022

NCT ID
NCT02279394

About Elotuzumab + Lenalidomide + Dexamethasone

Elotuzumab + Lenalidomide + Dexamethasone is a phase 2 stage product being developed by Bristol Myers Squibb for Smoldering Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT02279394. Target conditions include Smoldering Myeloma, Smoldering Multiple Myeloma.

What happened to similar drugs?

0 of 1 similar drugs in Smoldering Myeloma were approved

Approved (0) Terminated (0) Active (1)
🔄Linvoseltamab + DaratumumabRegeneron PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT03411031Phase 2Terminated
NCT02843074Phase 2Completed
NCT02279394Phase 2Completed
NCT02159365Phase 2Completed

Competing Products

13 competing products in Smoldering Myeloma

See all competitors
ProductCompanyStageHype Score
Elotuzumab (BMS-901608; HuLuc63)AbbViePhase 2
35
BHQ880NovartisPhase 2
35
carfilzomib + Lenalidomide + Dexamethasone + MelphalanAmgenPhase 2
39
DenosumabAmgenPhase 2
35
Carfilzomib + Lenalidomide + Daratumumab + DexamethasoneAmgenPhase 2
39
ElranatamabPfizerPhase 2
42
Nivolumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
35
Dexamethasone + Iberdomide HydrochlorideBristol Myers SquibbPhase 2
42
LinvoseltamabRegeneron PharmaceuticalsPhase 2
39
Linvoseltamab + DaratumumabRegeneron PharmaceuticalsPhase 3
47
SelinexorKaryopharm TherapeuticsPhase 2
32
IPH2101Innate PharmaPhase 2
25
PD-L1 peptideIO BiotechPhase 2
17